Enanta Pharmaceuticals Inc Total Liabilities
Enanta Pharmaceuticals Inc total liabilities. Based on the latest financial reports, Enanta Pharmaceuticals Inc (ENTA) has total liabilities worth $195.80 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check ENTA asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Enanta Pharmaceuticals Inc (2011–2025)
Total liabilities of Enanta Pharmaceuticals Inc from 2011 to 2025. This chart illustrates how Enanta Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Explore ENTA strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Enanta Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Enanta Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
BK Technologies Inc
NYSE MKT:BKTI
|
USA | $19.06 Million |
|
Bourrelier Group SA
PA:ALBOU
|
France | €234.27 Million |
|
HLE Glascoat Limited
NSE:HLEGLAS
|
India | Rs7.64 Billion |
|
Divgi Torqtransfer Systems Limited
NSE:DIVGIITTS
|
India | Rs809.29 Million |
|
Halk Gayrimenkul Yatirim Ortakligi AS
IS:HLGYO
|
Turkey | TL37.86 Billion |
|
Suzhou Fushilai Pharmaceutical Co. Ltd.
SHE:301258
|
China | CN¥211.52 Million |
|
Biofarm Bucure
RO:BIO
|
Romania | RON85.86 Million |
|
Guangdong Real-Design Intelligent Technology Co. Ltd.
SHE:301135
|
China | CN¥1.03 Billion |
Liability Composition Analysis (2011–2025)
This chart breaks down Enanta Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see ENTA asset base.
Liquidity & Leverage Metrics
Enanta Pharmaceuticals Inc Total Liabilities Ratios Explained
Enanta Pharmaceuticals Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.76 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.94 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.66 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Enanta Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Enanta Pharmaceuticals Inc (2011–2025)
The table below shows the annual total liabilities of Enanta Pharmaceuticals Inc from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-09-30 | $216.01 Million | -12.84% |
| 2024-09-30 | $247.84 Million | +0.94% |
| 2023-09-30 | $245.54 Million | +314.37% |
| 2022-09-30 | $59.26 Million | +43.02% |
| 2021-09-30 | $41.43 Million | +17.67% |
| 2020-09-30 | $35.21 Million | +28.80% |
| 2019-09-30 | $27.34 Million | +33.04% |
| 2018-09-30 | $20.55 Million | -17.68% |
| 2017-09-30 | $24.96 Million | +120.10% |
| 2016-09-30 | $11.34 Million | +15.07% |
| 2015-09-30 | $9.86 Million | +45.78% |
| 2014-09-30 | $6.76 Million | +3.94% |
| 2013-09-30 | $6.50 Million | -20.99% |
| 2012-09-30 | $8.23 Million | -94.79% |
| 2011-09-30 | $158.06 Million | -- |
About Enanta Pharmaceuticals Inc
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respirato… Read more